Home Improvement
Compare Stocks
5 / 10Stock Comparison
PFAI vs ACMR vs INTC vs ICHR vs NVDA
Revenue, margins, valuation, and 5-year total return — side by side.
Semiconductors
Semiconductors
Semiconductors
Semiconductors
PFAI vs ACMR vs INTC vs ICHR vs NVDA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Home Improvement | Semiconductors | Semiconductors | Semiconductors | Semiconductors |
| Market Cap | $31M | $3.92B | $550.40B | $2.47B | $5.14T |
| Revenue (TTM) | $3M | $901M | $53.76B | $959M | $215.94B |
| Net Income (TTM) | $286K | $94M | $-3.17B | $-51M | $120.07B |
| Gross Margin | 47.3% | 44.4% | 35.4% | 11.3% | 71.1% |
| Operating Margin | 18.7% | 12.1% | -9.4% | -3.8% | 60.4% |
| Forward P/E | 190.5x | 29.7x | 105.1x | 62.2x | 25.6x |
| Total Debt | $163K | $303M | $46.59B | $186M | $11.41B |
| Cash & Equiv. | $686K | $766M | $14.27B | $98M | $10.61B |
PFAI vs ACMR vs INTC vs ICHR vs NVDA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 25 | May 26 | Return |
|---|---|---|---|
| Pinnacle Food Group… (PFAI) | 100 | 126.4 | +26.4% |
| ACM Research, Inc. (ACMR) | 100 | 304.1 | +204.1% |
| Intel Corporation (INTC) | 100 | 545.4 | +445.4% |
| Ichor Holdings, Ltd. (ICHR) | 100 | 360.1 | +260.1% |
| NVIDIA Corporation (NVDA) | 100 | 194.2 | +94.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PFAI vs ACMR vs INTC vs ICHR vs NVDA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PFAI is the #2 pick in this set and the best alternative if stability is your priority.
- Beta 0.53 vs ICHR's 3.93
ACMR ranks third and is worth considering specifically for income & stability.
- Dividend streak 3 yrs, beta 3.24, yield 0.2%
- 0.2% yield, 3-year raise streak, vs NVDA's 0.0%, (3 stocks pay no dividend)
INTC is the clearest fit if your priority is momentum.
- +439.7% vs PFAI's +26.8%
Among these 5 stocks, ICHR doesn't own a clear edge in any measured category.
NVDA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 65.5%, EPS growth 66.7%, 3Y rev CAGR 100.0%
- 239.0% 10Y total return vs ACMR's 30.7%
- Lower volatility, beta 1.73, Low D/E 7.3%, current ratio 3.91x
- PEG 0.27 vs ACMR's 0.84
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 65.5% revenue growth vs INTC's -0.5% | |
| Value | Lower P/E (25.6x vs 62.2x) | |
| Quality / Margins | 55.6% margin vs INTC's -5.9% | |
| Stability / Safety | Beta 0.53 vs ICHR's 3.93 | |
| Dividends | 0.2% yield, 3-year raise streak, vs NVDA's 0.0%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +439.7% vs PFAI's +26.8% | |
| Efficiency (ROA) | 58.1% ROA vs ICHR's -5.2%, ROIC 81.8% vs -3.9% |
PFAI vs ACMR vs INTC vs ICHR vs NVDA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
PFAI vs ACMR vs INTC vs ICHR vs NVDA — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NVDA leads in 3 of 6 categories
ACMR leads 1 • PFAI leads 0 • INTC leads 0 • ICHR leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
NVDA leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVDA is the larger business by revenue, generating $215.9B annually — 65637.4x PFAI's $3M. NVDA is the more profitable business, keeping 55.6% of every revenue dollar as net income compared to INTC's -5.9%. On growth, NVDA holds the edge at +73.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3M | $901M | $53.8B | $959M | $215.9B |
| EBITDAEarnings before interest/tax | — | $126M | $4.0B | -$11M | $133.2B |
| Net IncomeAfter-tax profit | — | $94M | -$3.2B | -$51M | $120.1B |
| Free Cash FlowCash after capex | — | -$69M | -$3.1B | -$17M | $96.7B |
| Gross MarginGross profit ÷ Revenue | +47.3% | +44.4% | +35.4% | +11.3% | +71.1% |
| Operating MarginEBIT ÷ Revenue | +18.7% | +12.1% | -9.4% | -3.8% | +60.4% |
| Net MarginNet income ÷ Revenue | +8.7% | +10.4% | -5.9% | -5.3% | +55.6% |
| FCF MarginFCF ÷ Revenue | -27.2% | -7.6% | -5.8% | -1.7% | +44.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +9.4% | +7.2% | +4.7% | +73.2% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -76.1% | -2.8% | +46.2% | +97.8% |
Valuation Metrics
Evenly matched — ACMR and NVDA each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 43.2x trailing earnings, NVDA trades at a 77% valuation discount to PFAI's 190.5x P/E. Adjusting for growth (PEG ratio), NVDA offers better value at 0.45x vs ACMR's 1.22x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $31M | $3.9B | $550.4B | $2.5B | $5.14T |
| Enterprise ValueMkt cap + debt − cash | $30M | $3.5B | $582.7B | $2.6B | $5.14T |
| Trailing P/EPrice ÷ TTM EPS | 190.52x | 43.21x | -1861.12x | -46.25x | 43.16x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 29.68x | 105.10x | 62.25x | 25.55x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.22x | — | — | 0.45x |
| EV / EBITDAEnterprise value multiple | 31.75x | 27.49x | 49.88x | — | 38.59x |
| Price / SalesMarket cap ÷ Revenue | 9.40x | 4.35x | 10.41x | 2.61x | 23.80x |
| Price / BookPrice ÷ Book value/share | 85.30x | 2.06x | 4.21x | 3.67x | 32.85x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 53.17x |
Profitability & Efficiency
NVDA leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
NVDA delivers a 76.3% return on equity — every $100 of shareholder capital generates $76 in annual profit, vs $-8 for ICHR. NVDA carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to INTC's 0.37x. On the Piotroski fundamental quality scale (0–9), PFAI scores 6/9 vs ACMR's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +61.3% | +6.1% | -2.7% | -7.5% | +76.3% |
| ROA (TTM)Return on assets | +6.1% | +3.9% | -1.6% | -5.2% | +58.1% |
| ROICReturn on invested capital | — | +7.0% | -0.0% | -3.9% | +81.8% |
| ROCEReturn on capital employed | +34.7% | +6.6% | -0.0% | -4.7% | +97.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 2 | 6 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.35x | 0.16x | 0.37x | 0.28x | 0.07x |
| Net DebtTotal debt minus cash | -$523,124 | -$463M | $32.3B | $87M | $807M |
| Cash & Equiv.Liquid assets | $685,796 | $766M | $14.3B | $98M | $10.6B |
| Total DebtShort + long-term debt | $162,672 | $303M | $46.6B | $186M | $11.4B |
| Interest CoverageEBIT ÷ Interest expense | — | 20.44x | 3.71x | -5.97x | 545.03x |
Total Returns (Dividends Reinvested)
NVDA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NVDA five years ago would be worth $142,893 today (with dividends reinvested), compared to $10,050 for PFAI. Over the past 12 months, INTC leads with a +439.7% total return vs PFAI's +26.8%. The 3-year compound annual growth rate (CAGR) favors NVDA at 93.6% vs PFAI's 0.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +85.3% | +31.9% | +178.4% | +249.0% | +12.0% |
| 1-Year ReturnPast 12 months | +26.8% | +195.6% | +439.7% | +329.1% | +80.7% |
| 3-Year ReturnCumulative with dividends | +0.5% | +487.9% | +258.3% | +151.1% | +625.9% |
| 5-Year ReturnCumulative with dividends | +0.5% | +133.4% | +95.8% | +28.9% | +1328.9% |
| 10-Year ReturnCumulative with dividends | +0.5% | +3065.8% | +299.2% | +629.1% | +23902.3% |
| CAGR (3Y)Annualised 3-year return | +0.2% | +80.5% | +53.0% | +35.9% | +93.6% |
Risk & Volatility
Evenly matched — PFAI and ICHR each lead in 1 of 2 comparable metrics.
Risk & Volatility
PFAI is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than ICHR's 3.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ICHR currently trades 97.7% from its 52-week high vs PFAI's 81.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.53x | 3.24x | 2.15x | 3.93x | 1.73x |
| 52-Week HighHighest price in past year | $4.93 | $71.65 | $114.51 | $72.87 | $216.80 |
| 52-Week LowLowest price in past year | $1.30 | $19.26 | $18.97 | $13.12 | $112.28 |
| % of 52W HighCurrent price vs 52-week peak | +81.5% | +82.6% | +95.7% | +97.7% | +97.6% |
| RSI (14)Momentum oscillator 0–100 | 55.6 | 60.7 | 85.9 | 66.9 | 60.7 |
| Avg Volume (50D)Average daily shares traded | 8K | 1.2M | 110.6M | 795K | 164.5M |
Analyst Outlook
ACMR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ACMR as "Buy", INTC as "Hold", ICHR as "Buy", NVDA as "Buy". Consensus price targets imply 31.8% upside for NVDA (target: $279) vs -32.4% for ACMR (target: $40). ACMR is the only dividend payer here at 0.19% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | — | $40.00 | $77.18 | $49.80 | $278.83 |
| # AnalystsCovering analysts | — | 10 | 84 | 14 | 79 |
| Dividend YieldAnnual dividend ÷ price | — | +0.2% | — | — | +0.0% |
| Dividend StreakConsecutive years of raises | — | 3 | 0 | 1 | 2 |
| Dividend / ShareAnnual DPS | — | $0.11 | — | — | $0.04 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.2% | 0.0% | 0.0% | +0.8% |
NVDA leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ACMR leads in 1 (Analyst Outlook). 2 tied.
PFAI vs ACMR vs INTC vs ICHR vs NVDA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PFAI or ACMR or INTC or ICHR or NVDA a better buy right now?
For growth investors, NVIDIA Corporation (NVDA) is the stronger pick with 65.
5% revenue growth year-over-year, versus -0. 5% for Intel Corporation (INTC). NVIDIA Corporation (NVDA) offers the better valuation at 43. 2x trailing P/E (25. 6x forward), making it the more compelling value choice. Analysts rate ACM Research, Inc. (ACMR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PFAI or ACMR or INTC or ICHR or NVDA?
On trailing P/E, NVIDIA Corporation (NVDA) is the cheapest at 43.
2x versus Pinnacle Food Group Limited Class A Common Shares at 190. 5x. On forward P/E, NVIDIA Corporation is actually cheaper at 25. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: NVIDIA Corporation wins at 0. 27x versus ACM Research, Inc. 's 0. 84x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — PFAI or ACMR or INTC or ICHR or NVDA?
Over the past 5 years, NVIDIA Corporation (NVDA) delivered a total return of +1329%, compared to +0.
5% for Pinnacle Food Group Limited Class A Common Shares (PFAI). Over 10 years, the gap is even starker: NVDA returned +239. 0% versus PFAI's +0. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PFAI or ACMR or INTC or ICHR or NVDA?
By beta (market sensitivity over 5 years), Pinnacle Food Group Limited Class A Common Shares (PFAI) is the lower-risk stock at 0.
53β versus Ichor Holdings, Ltd. 's 3. 93β — meaning ICHR is approximately 639% more volatile than PFAI relative to the S&P 500. On balance sheet safety, NVIDIA Corporation (NVDA) carries a lower debt/equity ratio of 7% versus 37% for Intel Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — PFAI or ACMR or INTC or ICHR or NVDA?
By revenue growth (latest reported year), NVIDIA Corporation (NVDA) is pulling ahead at 65.
5% versus -0. 5% for Intel Corporation (INTC). On earnings-per-share growth, the picture is similar: Intel Corporation grew EPS 98. 7% year-over-year, compared to -140. 6% for Ichor Holdings, Ltd.. Over a 3-year CAGR, NVDA leads at 100. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PFAI or ACMR or INTC or ICHR or NVDA?
NVIDIA Corporation (NVDA) is the more profitable company, earning 55.
6% net margin versus -5. 6% for Ichor Holdings, Ltd. — meaning it keeps 55. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVDA leads at 60. 4% versus -4. 1% for ICHR. At the gross margin level — before operating expenses — NVDA leads at 71. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PFAI or ACMR or INTC or ICHR or NVDA more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, NVIDIA Corporation (NVDA) is the more undervalued stock at a PEG of 0. 27x versus ACM Research, Inc. 's 0. 84x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, NVIDIA Corporation (NVDA) trades at 25. 6x forward P/E versus 105. 1x for Intel Corporation — 79. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVDA: 31. 8% to $278. 83.
08Which pays a better dividend — PFAI or ACMR or INTC or ICHR or NVDA?
In this comparison, ACMR (0.
2% yield) pays a dividend. PFAI, INTC, ICHR, NVDA do not pay a meaningful dividend and should not be held primarily for income.
09Is PFAI or ACMR or INTC or ICHR or NVDA better for a retirement portfolio?
For long-horizon retirement investors, Pinnacle Food Group Limited Class A Common Shares (PFAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
53)). ACM Research, Inc. (ACMR) carries a higher beta of 3. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PFAI: +0. 5%, ACMR: +30. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PFAI and ACMR and INTC and ICHR and NVDA?
These companies operate in different sectors (PFAI (Consumer Cyclical) and ACMR (Technology) and INTC (Technology) and ICHR (Technology) and NVDA (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: PFAI is a small-cap high-growth stock; ACMR is a small-cap high-growth stock; INTC is a large-cap quality compounder stock; ICHR is a small-cap quality compounder stock; NVDA is a mega-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.